NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 44 filers reported holding NEUROCRINE BIOSCIENCES INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $33,829,158,000 | +16.8% | 25,450,000 | +18.6% | 0.01% | +7.7% |
| Q1 2021 | $28,956,213,000 | -2.9% | 21,450,000 | 0.0% | 0.01% | -7.1% |
| Q4 2020 | $29,821,721,000 | +27.6% | 21,450,000 | +26.5% | 0.01% | +7.7% |
| Q3 2020 | $23,362,863,000 | +0.9% | 16,950,000 | +21.5% | 0.01% | -7.1% |
| Q2 2020 | $23,155,884,000 | +10.9% | 13,950,000 | -14.7% | 0.01% | -6.7% |
| Q1 2020 | $20,871,593,000 | -16.5% | 16,350,000 | 0.0% | 0.02% | 0.0% |
| Q4 2019 | $25,001,603,000 | +5.0% | 16,350,000 | -5.8% | 0.02% | -6.2% |
| Q3 2019 | $23,803,333,000 | +4.0% | 17,350,000 | 0.0% | 0.02% | 0.0% |
| Q2 2019 | $22,878,057,000 | -2.6% | 17,350,000 | 0.0% | 0.02% | -5.9% |
| Q1 2019 | $23,492,768,000 | +2.1% | 17,350,000 | -10.3% | 0.02% | -15.0% |
| Q4 2018 | $23,000,378,000 | -50.7% | 19,350,000 | -29.3% | 0.02% | -42.9% |
| Q3 2018 | $46,673,322,000 | -8.3% | 27,350,000 | -22.6% | 0.04% | -10.3% |
| Q2 2018 | $50,914,605,000 | – | 35,350,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| III Capital Management | 12,500,000 | $17,262,000 | 3.12% |
| CSS LLC/IL | 24,395,000 | $33,616,000 | 1.59% |
| Mint Tower Capital Management B.V. | 9,000,000 | $12,407,000 | 1.46% |
| Context Partners Fund, L.P. | 3,000,000 | $4,125,000 | 0.90% |
| Context Capital Management, LLC | 3,000,000 | $4,125,000 | 0.90% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,258,000 | $5,971,000 | 0.71% |
| SSI INVESTMENT MANAGEMENT LLC | 5,888,000 | $8,100,000 | 0.70% |
| Aequim Alternative Investments LP | 3,000,000 | $4,155,000 | 0.55% |
| WOLVERINE ASSET MANAGEMENT LLC | 32,181,000 | $44,437,000 | 0.40% |
| TWO SIGMA SECURITIES, LLC | 13,000,000 | $17,875,000 | 0.36% |